• AJJ Medtech Holdings’ third-quarter net loss narrowed 25% year-over-year to SGD 594,000, while revenue rose 24% to SGD 598,000.
• For 9M2026, net loss widened 14% year-over-year to SGD 1.94 million, while revenue fell 19% to SGD 1.82 million.
• Cash totaled SGD 54,000 at September 30, 2026, while net current liabilities reached SGD 4.11 million.
• The first commercial order for AJJ-branded hemodialyzers was announced October 26; billing had not commenced by November 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AJJ Medtech Holdings Ltd published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: UGU6BIB0ODLH7T7H) on November 10, 2026, and is solely responsible for the information contained therein.